Most Liquid Pharmaceuticals, Biotechnology & Life Sciences Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
233.74 B
(0.04)
 1.13 
(0.05)
2NVO Novo Nordisk AS
37.47 B
 0.03 
 2.35 
 0.06 
3GMAB Genmab AS
21.61 B
 0.19 
 2.27 
 0.43 
4NEUP Neuphoria Therapeutics
14.92 B
 0.03 
 14.31 
 0.48 
5MRK Merck Company
13.24 B
 0.08 
 1.69 
 0.14 
6ABBV AbbVie Inc
11.88 B
 0.12 
 1.43 
 0.18 
7AMGN Amgen Inc
11.48 B
 0.00 
 1.53 
 0.01 
8BMY Bristol Myers Squibb
10.35 B
 0.03 
 1.61 
 0.06 
9VRTX Vertex Pharmaceuticals
9.77 B
(0.04)
 2.93 
(0.11)
10BNTX BioNTech SE
9.33 B
(0.03)
 2.31 
(0.06)
11NVS Novartis AG ADR
8.87 B
 0.07 
 1.25 
 0.08 
12MRNA Moderna
8.35 B
 0.01 
 3.44 
 0.03 
13REGN Regeneron Pharmaceuticals
7.02 B
 0.10 
 2.37 
 0.23 
14SNY Sanofi ADR
6.9 B
 0.05 
 1.92 
 0.10 
15GILD Gilead Sciences
6.14 B
 0.06 
 1.64 
 0.09 
16JNJ Johnson Johnson
5.37 B
 0.22 
 0.74 
 0.17 
17BIIB Biogen Inc
4.91 B
 0.12 
 2.17 
 0.26 
18AZN AstraZeneca PLC ADR
4.52 B
 0.11 
 1.67 
 0.18 
19GLPG Galapagos NV ADR
4.43 B
(0.02)
 2.17 
(0.05)
20TMO Thermo Fisher Scientific
4.01 B
 0.17 
 1.94 
 0.32 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).